Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer

Charles A. Kunos, Denise Fabian, Tricia Fredericks, Lauren Baldwin, Charles Dietrich, Rachel W. Miller, Frederick R. Ueland

Research output: Contribution to journalArticlepeer-review


Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.

Original languageEnglish
Article number1132135
JournalFrontiers in Oncology
StatePublished - 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 Kunos, Fabian, Fredericks, Baldwin, Dietrich, Miller and Ueland.


  • Appalachia
  • cervical cancer
  • hemoglobin
  • survival
  • uterine cervix

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer'. Together they form a unique fingerprint.

Cite this